KALA (KALA BIO) חוב לטווח קצר להון

KALA BIO, Inc. (KALA) is developing the innovative MSC-Exo system to combat orphan vision pathologies, aiming to capture untapped market segments. Intellectual property protection and capital-intensive research create significant barriers to entry for new players. The price indicator on this chart demonstrates a debt-to-equity ratio, which currently stands at 0.00. The project's stability relies on successful corneal therapy tests and sufficient R&D funding.

KALA BIO, Inc. (KALA) leverages AI to automate the synthesis of ophthalmological drugs, yet the costs of clinical trials necessitate immediate funding. This metric correlates the volume of short-term loans with net assets to measure liquidity dependence on external borrowings. The price action of short-term liabilities relative to equity allows for an assessment of the risk of cash flow gaps between testing phases. Investors utilize this indicator to monitor the company's solvency during periods of high capital intensity.